Represcription of low-dose acetylsalicylic acid after discontinuation in patients receiving treatment for secondary cardiovascular disease prevention in the UK

American Journal of Cardiovascular Drugs

Volumn 14, Issue 4, 2014, Pages 319-326

  Martín Merino, Elisa ^a   Johansson, Saga ^b   Nagy, Péter ^b   Rodríguez, Luis A García ^a  

^a Spanish Centre for Pharmacoepidemiologic Research ^*  (Spain)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMAN; INCIDENCE; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PRIMARY HEALTH CARE; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; RISK FACTORS; SECONDARY PREVENTION;

EID: 84905917635     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-014-0079-y     Document Type: Article

References (21)

1. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635-701.
2. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118(18):1894-909.
3. García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;28(123):1108-15.
4. García Rodríguez LA, Cea Soriano L, Hill C, Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology. 2011;76(8):740-6.
5. García Rodríguez LA, Cea Soriano L, Martín-Merino E, Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ. 2011;343:d4094.
6. Collet JP, Himbet F, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol. 2000;76(2-3):257-8.
7. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005;62(8):1217-20. (Pubitemid 41168347)
8. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005;45(3):456-9. (Pubitemid 40186800)
9. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22):2667-74. (Pubitemid 44729867)
10. Engelen S, Sinnaeve P, Van Damme H, Verhamme P. Antiplatelet therapy in the perioperative period. Acta Anaesthesiol Belg. 2010;61(3):139-43.
11. Martín-Merino E, Johansson S, Bueno H, García Rodríguez L. Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease. Prag Obs Res. 2012;3:1-9.
12. Cegedim. THIN Data Statistics. 2012 [cited 20 December 2012]. http://csdmruk.cegedim.com.
13. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12(3):171-7. (Pubitemid 39534583)
14. Lin KJ, Hernández-Diaz S, Rodríguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology. 2011;30(141):71-9.
15. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of The Health Improvement Network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16(4):393-401. (Pubitemid 46656860)
16. Loewen P, Sunderji R, Gin K. The efficacy and safety of combination warfarin and ASA therapy: a systematic review of the literature and update of guidelines. Can J Cardiol. 1998;14(5):717-26. (Pubitemid 28276713)
17. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011;154(3):311-24.
18. Bytzer P, Pratt S, Elkin E, Næsdal J, Sörstadius E. Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study. Am J Cardiovasc Drugs. 2013;13(1):27-35.
19. Herlitz J, Toth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010;10(2):125-41.
20. Hopper S, Pierce M. Aspirin after myocardial infarction: the importance of over-the-counter use. Fam Pract. 1998;15(Suppl 1):S10-3. (Pubitemid 28200709)
21. Bedson J, Whitehurst T, Lewis M, Croft P. Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease. Br J Gen Pract. 2001;51(473):1001-3. (Pubitemid 33138291)